James G. Herman

Q: What Schools Are Affiliated With James G. Herman

James G. Herman is affiliated with the following schools: Icahn School of Medicine at Mount Sinai, Case Western Reserve University, University of New Mexico, Johns Hopkins University, University of Pittsburgh, University of Barcelona, Burgundy - Franche-Comté University Group, Ghent University, Hope College

James G. Herman's AcademicInfluence.com Rankings

James G. Herman

Medical

#395

World Rank

#552

Historical Rank

Oncology

#22

World Rank

#23

Historical Rank

medical Degrees

James G. Herman

Philosophy

#3096

World Rank

#5082

Historical Rank

Logic

#997

World Rank

#1612

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

James G. Herman's Degrees

Doctorate Medicine Johns Hopkins University
PhD Oncology Johns Hopkins University

Why Is James G. Herman Influential?

(Suggest an Edit or Addition)

According to Wikipedia, James Gordon Herman is an American oncologist. Herman studied chemistry at Hope College and earned a medical degree from the Johns Hopkins School of Medicine. He completed his residency in internal medicine at Duke University in 1992, and a fellowship in medical oncology at Johns Hopkins in 1996. Herman then became associate professor of oncology at the Sidney Kimmel Comprehensive Cancer Center, and later the UPMC Endowed Chair for Lung Cancer Research at the University of Pittsburgh.

(See a Problem?)

James G. Herman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Integrated Genomic Analyses of Ovarian Carcinoma (2011) (6411)
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. (1996) (5875)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways (2008) (5775)
Comprehensive molecular characterization of gastric adenocarcinoma (2014) (4496)
Comprehensive molecular profiling of lung adenocarcinoma (2014) (4095)
Gene silencing in cancer in association with promoter hypermethylation. (2003) (3338)
Comprehensive genomic characterization of squamous cell lung cancers (2012) (2998)
Comprehensive genomic characterization of head and neck squamous cell carcinomas (2015) (2860)
CpG island methylator phenotype in colorectal cancer. (1999) (2332)
A gene hypermethylation profile of human cancer. (2001) (2156)
Genomic Classification of Cutaneous Melanoma (2015) (2143)
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. (2010) (2121)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. (2000) (2115)
5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers (1995) (2108)
Alterations in DNA methylation: a fundamental aspect of neoplasia. (1998) (2064)
Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014) (2007)
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. (1998) (2005)
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer (1999) (1933)
DNA hypermethylation in tumorigenesis: epigenetics joins genetics. (2000) (1685)
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. (1994) (1630)
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. (1995) (1490)
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. (1999) (1244)
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. (2000) (1188)
A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing (2007) (1100)
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer (2004) (1075)
Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. (1998) (1004)
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma (2001) (990)
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. (1999) (982)
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. (2001) (939)
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer (2006) (931)
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer (2002) (877)
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. (1995) (876)
Predicting lung cancer by detecting aberrant promoter methylation in sputum. (2000) (850)
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas (2016) (826)
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours (2002) (773)
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. (1997) (759)
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. (2008) (747)
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity (2001) (709)
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. (1997) (673)
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. (1996) (649)
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. (2002) (605)
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. (2000) (574)
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. (2011) (569)
DNA methylation markers and early recurrence in stage I lung cancer. (2008) (561)
Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. (2000) (556)
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. (2000) (549)
Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. (2000) (523)
MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas (1998) (522)
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. (2006) (490)
CpG methylation is maintained in human cancer cells lacking DNMT1 (2000) (484)
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. (1997) (472)
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. (2001) (461)
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. (2003) (436)
DNA methylation, chromatin inheritance, and cancer (2001) (411)
Inhibition of SIRT1 Reactivates Silenced Cancer Genes without Loss of Promoter DNA Hypermethylation (2006) (406)
Methylation Patterns of the E-cadherin 5′ CpG Island Are Unstable and Reflect the Dynamic, Heterogeneous Loss of E-cadherin Expression during Metastatic Progression* (2000) (399)
Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. (1999) (397)
Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. (1999) (390)
Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. (1998) (388)
Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. (2002) (379)
Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. (2006) (378)
A systematic profile of DNA methylation in human cancer cell lines. (2003) (374)
Analysis of DNA methylation in cancer: location revisited (2018) (371)
Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. (2003) (371)
Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells (2001) (359)
Comparing the DNA Hypermethylome with Gene Mutations in Human Colorectal Cancer (2007) (358)
Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. (2001) (349)
Mapping Patterns of CpG Island Methylation in Normal and Neoplastic Cells Implicates Both Upstream and Downstream Regions inde Novo Methylation* (1997) (347)
Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. (1999) (346)
In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. (1999) (345)
Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. (1999) (343)
Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. (2001) (330)
Association between CpG island methylation and microsatellite instability in colorectal cancer. (1997) (324)
Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. (2003) (321)
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. (2003) (315)
hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. (1999) (315)
Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer (2004) (313)
Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. (1999) (308)
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. (2000) (306)
Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. (2002) (305)
Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation (2005) (292)
Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. (1998) (291)
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. (2003) (286)
Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. (2001) (276)
Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells. (1993) (270)
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. (2009) (261)
K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. (2001) (260)
GATA-4 and GATA-5 Transcription Factor Genes and Potential Downstream Antitumor Target Genes Are Epigenetically Silenced in Colorectal and Gastric Cancer (2003) (258)
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. (2001) (253)
Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. (2002) (251)
Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. (2003) (247)
p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. (1999) (243)
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. (2000) (240)
The fundamental role of epigenetics in hematopoietic malignancies. (2006) (231)
Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. (1998) (229)
Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. (2003) (225)
Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. (2000) (218)
Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients (2004) (218)
Hypermethylation of tumor suppressor genes in cancer. (1999) (215)
Abnormalities of the APC/β-catenin pathway in endometrial cancer (2002) (213)
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. (2009) (212)
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. (2014) (211)
Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors (2003) (210)
Carotenoids and the risk of developing lung cancer: a systematic review. (2008) (209)
PcG Proteins, DNA Methylation, and Gene Repression by Chromatin Looping (2008) (205)
Arsenic in drinking water and lung cancer: a systematic review. (2008) (203)
Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: Relationships with abnormal E‐cadherin and catenin expression and microsatellite instability (2003) (203)
Moving AHEAD with an international human epigenome project (2008) (202)
hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. (2007) (200)
Colorectal cancer epigenetics: complex simplicity. (2011) (198)
Low-level microsatellite instability in most colorectal carcinomas. (2002) (197)
Mapping of ER Gene CpG Island Methylation by Methylation-specific Polymerase Chain Reaction (1998) (197)
N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. (2009) (197)
Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome (2000) (194)
K-ras mutations and RASSF1A promoter methylation in colorectal cancer (2002) (192)
Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers (1998) (191)
Cruciferous Vegetable Consumption and Lung Cancer Risk: A Systematic Review (2009) (190)
Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. (1989) (188)
Methylation-specific PCR simplifies imprinting analysis. (1997) (182)
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer (1997) (182)
GATA4 and GATA5 are Potential Tumor Suppressors and Biomarkers in Colorectal Cancer (2009) (180)
Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. (2008) (177)
Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. (2002) (175)
Promoter-region hypermethylation and gene silencing in human cancer. (2000) (175)
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. (2007) (175)
Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum (2016) (173)
Aberrant Hypermethylation of Tumor Suppressor Genes in Pancreatic Endocrine Neoplasms (2003) (171)
Promoter Hypermethylation of Resected Bronchial Margins (2004) (169)
Seminoma of the testis: results of treatment and patterns of failure after radiation therapy. (1982) (166)
Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. (1998) (166)
DNA methylation changes in hematologic malignancies: biologic and clinical implications. (1997) (165)
Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. (2005) (163)
BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. (2010) (162)
Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. (2008) (161)
Frequent aberrant methylation of p16INK4a in primary rat lung tumors (1997) (158)
Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer. (2002) (157)
E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia. (2000) (156)
Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications (2009) (155)
Cancer Epigenetics and Methylation (2002) (153)
Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. (2003) (153)
The CpG island methylator phenotype: what's in a name? (2013) (152)
Convergence of Mutation and Epigenetic Alterations Identifies Common Genes in Cancer That Predict for Poor Prognosis (2008) (150)
Abnormalities of the APC/beta-catenin pathway in endometrial cancer. (2002) (147)
Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer (1999) (146)
Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer (2011) (143)
Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. (1998) (143)
Hypermethylation of the GATA Genes in Lung Cancer (2004) (142)
Analysis of Promoter CpG Island Hypermethylation in Cancer: Location, Location, Location! (2011) (141)
Mapping of ER gene CpG island methylation-specific polymerase chain reaction. (1998) (140)
Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1 (2006) (140)
p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. (2001) (140)
The Epigenetic promise for prostate cancer diagnosis (2012) (139)
Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma (2005) (138)
Whole‐exome sequencing of pancreatic neoplasms with acinar differentiation (2014) (138)
Aberrant methylation of gene promoters in cancer---concepts, misconcepts, and promise. (2000) (136)
Delayed Diagnosis and Elevated Mortality in an Urban Population With HIV and Lung Cancer: Implications for Patient Care (2006) (133)
DNA methylation changes in multiple myeloma (2004) (133)
MS-qFRET: a quantum dot-based method for analysis of DNA methylation. (2009) (131)
Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. (2008) (130)
Abnormalities of E‐ and P‐cadherin and catenin (β‐, γ‐catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia (2003) (129)
Hypermethylation in Histologically Distinct Classes of Breast Cancer (2004) (129)
Identification of epigenetically silenced genes in tumor endothelial cells. (2007) (129)
Methylation-specif ic PCR simplifies imprinting analysis (1997) (128)
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. (2012) (126)
SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma (2010) (126)
The CpG island methylator phenotype in colorectal cancer: progress and problems. (2012) (125)
DNA Promoter Hypermethylation of p16 and APC Predicts Neoplastic Progression in Barrett's Esophagus (2009) (125)
Methylation-Specific PCR Unraveled (2004) (124)
Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. (2008) (123)
Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. (2001) (123)
Beyond genetics: epigenetic code in chronic kidney disease. (2011) (122)
Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer (2013) (120)
The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation (2004) (118)
Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia (2001) (115)
DNA methylation profile associated with rapid decline in kidney function: findings from the CRIC study. (2014) (112)
Promoter Hypermethylation of Hallmark Cancer Genes in Atypical Adenomatous Hyperplasia of the Lung (2008) (112)
Epigenetic heterogeneity in cancer (2019) (112)
Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme (2007) (111)
Early Life Exposure to Famine and Colorectal Cancer Risk: A Role for Epigenetic Mechanisms (2009) (110)
Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. (1984) (109)
Accumulation of Promoter Methylation Suggests Epigenetic Progression in Squamous Cell Carcinoma of the Esophagus (2006) (105)
Adulthood consumption of preserved and nonpreserved vegetables and the risk of nasopharyngeal carcinoma: A systematic review (2006) (101)
Frequent hypermethylation of the 5' CpG island of E-cadherin in esophageal adenocarcinoma. (2001) (99)
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study (2016) (99)
Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. (1999) (97)
Specific Inhibition of DNMT1 by Antisense Oligonucleotides Induces Re-expression of Estrogen Receptor a (ER) in ER-negative Human Breast Cancer Cell Lines (2003) (95)
Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. (2006) (94)
Concurrent radiation, mitomycin C and 5-fluorouracil in poor prognosis carcinoma of cervix: preliminary results of a phase I-II study. (1984) (94)
CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. (2005) (94)
Defining a Gene Promoter Methylation Signature in Sputum for Lung Cancer Risk Assessment (2012) (94)
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders (2007) (93)
Epigenetic Regulation of WNT Signaling Pathway Genes in Inflammatory Bowel Disease (IBD) Associated Neoplasia (2008) (91)
Neurologic disorders in patients with small cell lung cancer (1987) (90)
Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia (2005) (89)
p21WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damage (2008) (87)
Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation (2010) (87)
Clustering of hypermethylated genes in neuroblastoma (2003) (86)
Superior vena caval obstruction syndrome in small cell lung cancer (1986) (82)
Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. (2003) (82)
Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. (2010) (81)
Autocatalytic oxidation of hemoglobin induced by nitrite: activation and chemical inhibition. (1985) (79)
Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. (2001) (78)
CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. (2002) (78)
Hypermethylation of a Small CpGuanine-Rich Region Correlates with Loss of Activator Protein-2α Expression during Progression of Breast Cancer (2004) (77)
A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors (2009) (75)
Epigenetic inactivation of secreted Frizzled‐related proteins in acute myeloid leukaemia (2008) (74)
Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer (2013) (74)
Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. (2010) (73)
The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer (2016) (73)
Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel–Lindau protein (2003) (73)
Hypermethylation of the GATA gene family in esophageal cancer (2006) (72)
Detection of radiation cardiomyopathy by gated radionuclide angiography. (1983) (72)
Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter (2007) (71)
Promoter Methylation Precedes Chromosomal Alterations in Colorectal Cancer Development (2006) (69)
Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. (2008) (69)
Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms. (2003) (69)
MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events. (2009) (68)
Epigenome-based personalized medicine in human cancer. (2016) (68)
Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior (2003) (67)
LKB1 Protein Expression in Human Breast Cancer (2006) (67)
A bird's eye view of global methylation (2000) (66)
Low incidence of loss of chromosome 10 in sporadic and hereditary human medullary thyroid carcinoma. (1989) (66)
Progression of Gene Hypermethylation in Gallstone Disease Leading to Gallbladder Cancer (2003) (63)
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. (2009) (63)
Predictive value of CHFR and MLH1 methylation in human gastric cancer (2015) (63)
Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer. (2012) (62)
Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer (2014) (61)
Alcohol Consumption and the Risk of Nasopharyngeal Carcinoma: A Systematic Review (2008) (60)
Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen (2012) (60)
Frequent Inactivation of Cysteine Dioxygenase Type 1 Contributes to Survival of Breast Cancer Cells and Resistance to Anthracyclines (2013) (59)
Alterations of the p16/Rb/cyclin-D1 pathway in vulvar carcinoma, vulvar intraepithelial neoplasia, and lichen sclerosus. (2002) (59)
Epigenetic silencing of multiple genes in primary CNS lymphoma (2006) (59)
Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer (2013) (57)
Enzymatic regional methylation assay: a novel method to quantify regional CpG methylation density. (2002) (56)
An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. (2008) (52)
Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21. (2009) (52)
SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer. (2012) (51)
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia (2016) (51)
Sessile serrated adenomas and classical adenomas: An epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract (2011) (51)
Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study (2016) (51)
Methylation of p 16 INK 4 a Promoters Occurs in Vivo in Histologically Normal Human Mammary Epithelia 1 (2003) (50)
Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome (2015) (50)
Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. (2001) (49)
Effect of DNA methylation on identification of aggressive prostate cancer. (2008) (49)
Methylated Tumor-Specific DNA as a Plasma Biomarker in Patients with Glioma (2006) (48)
Methylation-specific polymerase chain reaction. (2005) (48)
DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies (2015) (48)
Single-tube analysis of DNA methylation with silica superparamagnetic beads. (2010) (47)
Epigenetic Inactivation of Galanin Receptor 1 in Head and Neck Cancer (2008) (47)
Promoter hypermethylation--can this change alone ever designate true tumor suppressor gene function? (2001) (47)
Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. (2009) (47)
A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients (2016) (46)
DNA methylation analysis on a droplet-in-oil PCR array. (2009) (46)
Survival after community diagnosis of early-stage non-small cell lung cancer. (2014) (46)
Can we improve the cytologic examination of malignant pleural effusions using molecular analysis? (2005) (45)
Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer (2007) (45)
Prospective CT Screening for Lung Cancer in a High-Risk Population: HIV-Positive Smokers (2014) (45)
Promoter methylation of HIN-1 in the progression to esophageal squamous cancer (2008) (44)
Cancer as a manifestation of aberrant chromatin structure. (2007) (43)
Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia (2010) (43)
GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer (2017) (43)
Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc (2010) (43)
Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma. (2009) (42)
Methylation of TFPI 2 in Stool DNA : A Potential Novel Biomarker for the Detection of Colorectal Cancer (2009) (42)
A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1 (2010) (42)
Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer. (2017) (42)
Extraction and processing of circulating DNA from large sample volumes using methylation on beads for the detection of rare epigenetic events. (2013) (41)
Clonal analysis of a case of multiple meningiomas using multiple molecular genetic approaches: pathology case report. (1999) (40)
WNT10B functional dualism: beta-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer. (2007) (39)
DNA Methylation at the Novel CpG Sites in the Promoter of MED15/PCQAP Gene as a Biomarker for Head and Neck Cancers (2014) (38)
DACT2 is frequently methylated in human gastric cancer and methylation of DACT2 activated Wnt signaling. (2014) (38)
Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies (2005) (38)
DNA methylation mapping by tag-modified bisulfite genomic sequencing. (2006) (38)
Epigenetic changes and functional study of HOXA11 in human gastric cancer. (2015) (38)
Epigenetic regulation of the Wnt signaling inhibitor DACT2 in human hepatocellular carcinoma (2013) (38)
Epigenetic changes associated with neoplasms of the exocrine and endocrine pancreas. (2014) (38)
Promoter CpG island methylation markers in colorectal cancer: the road ahead. (2012) (38)
Evaluation of GATA-4 and GATA-5 methylation profiles in human pancreatic cancers indicate promoter methylation patterns distinct from other human tumor types (2007) (38)
Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer (2020) (37)
Circulating Methylated DNA (2004) (37)
Epigenetic silencing of CXCL14 induced colorectal cancer migration and invasion. (2013) (36)
Epigenetic regulation of protein phosphatase 2A (PP2A), Lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells (2004) (36)
Methylation of DACT2 Promotes Papillary Thyroid Cancer Metastasis by Activating Wnt Signaling (2014) (35)
Methylation of TFPI-2 is an early event of esophageal carcinogenesis. (2012) (35)
Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma (2017) (34)
Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine (2013) (34)
Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage. (2006) (34)
Methylation-specific PCR. (2001) (33)
Aberrant silencing of cancer-related genes by CpG hypermethylation occurs independently of their spatial organization in the nucleus. (2010) (33)
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia (2016) (33)
Methylation of DACT2 accelerates esophageal cancer development by activating Wnt signaling (2016) (33)
Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. (2004) (33)
Epigenetic changes in cancer and preneoplasia. (2005) (33)
Epigenetic silencing of neurofilament genes promotes an aggressive phenotype in breast cancer (2015) (32)
Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer by activating TGF-β signalling (2014) (32)
Epigenetic silencing of NKD2, a major component of Wnt signaling, promotes breast cancer growth (2015) (32)
Enzymatic Incorporation of Multiple Dyes for Increased Sensitivity in QD‐FRET Sensing for DNA Methylation Detection (2009) (32)
RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer. (2007) (31)
Silencing DACH1 Promotes Esophageal Cancer Growth by Inhibiting TGF-β Signaling (2014) (31)
Advances in Brief Inactivation of the DNA Repair Gene O 6-Methylguanine-DNA Methyltransferase by Promoter Hypermethylation is a Common Event in Primary Human Neoplasia 1 (1999) (31)
Epigenetics in lung cancer: focus on progression and early lesions. (2004) (31)
Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence (2017) (31)
Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients (2014) (30)
Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU (2015) (30)
Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel (2015) (29)
Facile profiling of molecular heterogeneity by microfluidic digital melt (2018) (29)
Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth (2017) (29)
A randomized trial of Melphalan alone versus combination chemotherapy in advanced ovarian cancer (1980) (29)
Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. (2008) (28)
A randomized clinical trial of moving strip versus open field whole abdominal irradiation in patients with invasive epithelial cancer of the ovary (1984) (28)
Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma (2011) (28)
Silencing NKD2 by Promoter Region Hypermethylation Promotes Esophageal Cancer Progression by Activating Wnt Signaling (2016) (28)
Spectrin Repeat Containing Nuclear Envelope 1 and Forkhead Box Protein E1 Are Promising Markers for the Detection of Colorectal Cancer in Blood (2014) (28)
Aberrant DNA methylation of the transcription factor C/EBPalpha in acute myelogenous leukemia. (2009) (27)
Silencing NKD2 by promoter region hypermethylation promotes gastric cancer invasion and metastasis by up-regulating SOX18 in human gastric cancer (2015) (27)
CHFR Promoter Methylation Indicates Poor Prognosis in Stage II Microsatellite Stable Colorectal Cancer (2013) (26)
Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450 (2006) (26)
Methylation-specific PCR. (2009) (25)
Epigenetic silencing BCL6B induced colorectal cancer proliferation and metastasis by inhibiting P53 signaling. (2015) (24)
Author Correction: Analysis of DNA methylation in cancer: location revisited (2018) (24)
Loss of a single Hic1 allele accelerates polyp formation in ApcΔ716 mice (2011) (24)
Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer. (2017) (24)
Advances in epigenetic therapeutics with focus on solid tumors (2021) (23)
Expression of prokaryotic HhaI DNA methyltransferase is transforming and lethal to NIH 3T3 cells. (1996) (23)
p16(INK4): involvement early and often in gastrointestinal malignancies. (1999) (22)
Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacitidine and Sodium Phenylbutyrate. (2004) (22)
CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer (2014) (22)
CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC (2013) (22)
Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules (2020) (22)
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms (2016) (21)
Advances in Brief Inactivation of the DNA Repair Gene O 6-Methylguanine-DNA Methyltransferase by Promoter Hypermethylation Is Associated with G to A Mutations in Kras in Colorectal Tumorigenesis 1 (2000) (21)
Methylation of TMEM176A is an independent prognostic marker and is involved in human colorectal cancer development (2017) (21)
CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non-small cell lung cancer. (2015) (20)
RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel (2015) (20)
Array‐based DNA methylation profiling in acute myeloid leukaemia (2011) (20)
RASSF10 suppresses hepatocellular carcinoma growth by activating P53 signaling and methylation of RASSF10 is a docetaxel resistant marker (2015) (20)
DNA-intercalators Causing Rapid Re-expression of Methylated and Silenced Genes in Cancer Cells (2013) (20)
A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET) (2016) (19)
Loss of chromosome arms 3p and 9p and inactivation of P16 INK4a in normal epithelium of patients with primary lung cancer (2001) (19)
Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer (2018) (18)
Short course prophylactic cranial irradiation for small cell lung cancer (1985) (17)
Epigenetic silencing of TMEM176A promotes esophageal squamous cell cancer development (2017) (17)
Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML) (2010) (17)
Decreased expression and promoter methylation of the menin tumor suppressor in pancreatic ductal adenocarcinoma (2009) (17)
A Gene Hypermethylation Profile of Human Cancer 1 (2001) (17)
Id1 expression is transcriptionally regulated in radial growth phase melanomas (2007) (16)
Spreadsheet-based program for the analysis of DNA methylation. (2001) (16)
Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma (2018) (16)
CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer (2012) (16)
PSEUDO‐GRAFT‐VERSUS‐HOST DISEASE IN HEART AND HEART‐LUNG RECIPIENTS (1988) (16)
Hypermethylation pathways to colorectal cancer. Implications for prevention and detection. (2002) (15)
Human Cancers Associated with Aberrant DNA Methylation in All Common Gene Is Frequently CDKN 2 / p 16 / MTS 1 Inactivation of the Updated (2006) (15)
Common genetic evolutionary pathways in familial adenomatous polyposis tumors. (2003) (14)
Standardized approach for microsatellite instability detection in gastric carcinomas. (2004) (14)
CpG Island Methylation ′ Associated with 5 Lymphoblastic Leukemia and Burkitt ' s Lymphoma Is Gene in Acute p 73 Transcriptional Silencing of the Updated Version (1999) (13)
Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation (2020) (13)
Inactivation of LKB 1 / STK 11 Is a Common Event in Adenocarcinomas of the Lung 1 (2002) (13)
Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis (2022) (13)
Identification of DNA methylation markers for early detection of CRC indicates a role for nervous system-related genes in CRC (2021) (12)
Phase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC) (2008) (12)
Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence (2009) (12)
Id1 overexpression is independent of repression and epigenetic silencing of tumor suppressor genes in melanoma (2010) (11)
On Predicting lung cancer subtypes using ‘omic’ data from tumor and tumor-adjacent histologically-normal tissue (2016) (11)
PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies (2020) (11)
Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro. (2014) (10)
Hypermethylation of ASC / TMS 1 Is a Sputum Marker for Late-Stage Lung Cancer (2006) (10)
Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer (2017) (10)
Viewing the Epigenetics of Colorectal Cancer through the Window of Folic Acid Effects (2010) (10)
CHK 2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas (2002) (10)
RASSF 1 A methylation and Kras and B-raf mutations and recurrent endometrial cancer (2007) (9)
Results of LSA2-L2 therapy in children with high-risk acute lymphoblastic leukemia and non-Hodgkin's lymphoma. (1983) (9)
Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers. (2012) (9)
HIST1H2BB and MAGI2 Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer (2020) (9)
Progression of Prostate Carcinogenesis and Dietary Methyl Donors: Temporal Dependence (2011) (8)
Upper half body irradiation (UHBI) for extensive small cell carcinoma of the lung. (1981) (8)
Radical external beam radiation therapy for prostate carcinoma. (1984) (8)
Alterations of p 14 ARF , p 53 , and p 73 Genes Involved in the E 2 F-1-mediated Apoptotic Pathways in Non-Small Cell Lung Carcinoma (2001) (8)
Advances in Brief Aberrant Methylation of the Estrogen Receptor and E-Cadherin 5 * CpG Islands Increases with Malignant Progression in Human Breast Cancer 1 (2000) (8)
BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated miR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies (2019) (8)
Methylation of NRN1 is a novel synthetic lethal marker of PI3K‐Akt‐mTOR and ATR inhibitors in esophageal cancer (2021) (7)
WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy (2016) (7)
ACharacterize the Major Types of Hematological Malignancies 1 (2006) (7)
DNA methylation pro fi le associated with rapid decline in kidney function : fi ndings from the CRIC Study (2014) (7)
Expectant therapy for clinical stage A nonseminomatous germ-cell tsticular cancer? Maybe (1984) (7)
Semiautomatic detection of DNA methylation at CpG islands. (2005) (7)
Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. (2017) (7)
Erratum: Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter (Oncogene (2007) 26 (6229-6237) DOI:10.1038/sj.onc.1210433) (2007) (6)
Microsatellite instability in IBD-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, HMLH1 (2000) (6)
Cryptorchidism and non-seminomatous testis cancer. (1981) (6)
Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer (2017) (6)
Genetic and Epigenetic Defects in DNA Repair Lead to Synthetic Lethality of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in Aggressive Myeloproliferative Disorders (2011) (5)
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. (2019) (5)
Methylation of RASSF10 promotes cell proliferation and serves as a docetaxel resistant marker in human breast cancer. (2015) (5)
Advances in Brief Dependence of Histone Modifications and Gene Expression on DNA Hypermethylation in Cancer 1 , 2 (2002) (5)
Advances in Brief p 14 ARF Silencing by Promoter Hypermethylation Mediates Abnormal Intracellular Localization of MDM 21 (2001) (4)
Beyond the genetic lesions: gene inactivation by promoter hypermethylation in human cancer (2000) (3)
Abstract 94: Epigenetic silencing of CDO1 sustains viability of breast cancer cells via the reduction of cellular ROS (2012) (3)
P15INK4B is not mutated in adult familial myelodysplastic syndromes (2002) (3)
DNA Methylation and Inactivation of Tumor Suppressor Genes (1996) (3)
Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer. (2014) (3)
Methylation of TMEM176A, a key ERK signaling regulator, is a novel synthetic lethality marker of ATM inhibitors in human lung cancer. (2020) (3)
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias (2015) (3)
Welcome to Epigenomics. (2009) (3)
Inactivation of Glutathione 5-Transferase PI Gene by Promoter Hypermethylation in Human Neoplasia1 (1998) (2)
An interim analysis of a phase II study using an epigenetic biomarker (CHFR methylation status) to personalize chemotherapy in patients with operable esophageal cancer. (2014) (2)
DNA-methylation for the detection and distinction of 19 human malignancies (2021) (2)
Biomarker analysis for UPCI 14-118: Phase II study of pembrolizumab in combination with azacitidine in patients with refractory metastatic colorectal cancer. (2020) (2)
Epigenetic Silencing of BRCA1 Is Linked to Homologous Recombination Repair Defects and Elevated Mir-155 Expression in Myeloid Neoplasms (2014) (2)
Alterations of p14 ARF , p53 , and p73 Genes Involved in the E2F-1-mediated Apoptotic Pathways in Non-Small Cell Lung Carcinoma (2001) (2)
Epigenetic silencing BCL 6 B induced colorectal cancer proliferation and metastasis by inhibiting P 53 signaling (2015) (2)
A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype (2021) (2)
AN EVALUATION OF THE ASSOCIATION OF CDKN2B (P15) DNA METHYLATION WITH RESPONSE AND SURVIVAL IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) TREATED IN THE AZA-001 TRIAL (2010) (2)
A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study. (2013) (2)
Real-time polymerase chain reaction technique determines absolute copy number of plasma methylated MGMT gene promoter copies in newly diagnosed malignant glioma patients (2008) (2)
Systemic immune dysfunction in cancer patients driven by IL6 and IL8 induction of an inhibitory receptor module in peripheral CD8+ T cells (2020) (2)
Human immunodeficiency virus and lung cancer: differences in presentation and clinical course. (2005) (2)
Use of a 21-gene reverse transcriptase-polymerase chain reaction (RT-PCR) assay to guide therapy in 14 Michigan Breast Oncology Quality Initiative (MiBOQI) sites. (2010) (1)
Docetaxel in adjuvant therapy of breast cancer : results of the TAXIT 216 multicenter phase III trial ” (2008) (1)
negative Breast Cancer Cells α in Human ER-by DNA Methyltransferase and Histone Deacetylase Inhibition α Synergistic Activation of Functional Estrogen Receptor ( ER )-Updated Version (2001) (1)
SU-E-T-426: Feasibility of Stereotactic Body Radiation Therapy (SBRT) Treatment of Pancreatic Cancer Using Volumetric Modulated Arc Therapy (VMAT) with Active Breathing Control (ABC) (2015) (1)
A pilot study of concurrent radiation, mitomycin C and 5-Fluorouracil in poor prognosis carcinoma of cervix (1984) (1)
Abstract B43: Early detection biomarker of pancreatic cancer using a nanoparticle-based methylation assay (2011) (1)
Correction: A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET) (2017) (1)
Technical considerations in PCR-based assay design for diagnostic DNA methylation cancer biomarkers (2022) (1)
Epigenetic silencing of JAM3 promotes esophageal cancer development by activating Wnt signaling (2022) (1)
E-Cadherin Expression Is Silenced by DNA Hypermethylation in Human Breast and Prostate Carcinomas1 (2006) (1)
Improving Prostate Cancer Management: Clinical Utility of Epigenetics for Diagnosis and Prognosis (2013) (1)
The role of radiation in the management of seminoma. (1984) (1)
Decitabine-induced apoptosis is p53-independent and mediated through reactive oxygen species (ROS) production and caspase activation (2007) (1)
Monitoring methylation and gene expression in cancer. (2007) (1)
p53 expression after treatment with zebularine is not due to demethylation. (2006) (1)
Endocannabinoids as emerging suppressors of angiogenesis and breast tumor growth and metastatic spreading ” (2008) (1)
Cancer epigenetics and methylation [3] (multiple letters) (2002) (1)
Abstract 3679: Preliminary results from a patient group, excluded from the National Lung Cancer Screening Trial, who are at high risk for lung cancer- heavy smokers with HIV (2011) (1)
Definitive radiation therapy (XRT) in the management of bladder cancer (1984) (1)
Hypermethylation Can Selectively Silence Individual pltfnk4A AlÃ elesin Neoplasia1 (2006) (1)
Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer. (2013) (1)
Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine (2013) (1)
Blood-based screening for methylation changes in colorectal cancer patients using novel nanotechnologies. (2013) (1)
Acute Myeloid Leukemia Is Characterized by Wnt Pathway Inhibitor Promoter Methylation. (2008) (1)
High-throughput sample processing for methylation analysis in an automated, enclosed environment. (2021) (1)
Abstract LB-411: A phase II study of combination epigenetic therapy in advanced non-small cell lung cancer (2011) (1)
Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis (2022) (1)
Intensity Modulated Radiation Therapy (IMRT) for Rectal Cancer Can Reduce Acute Toxicities of Chemoradiation (2010) (1)
Novel score to predict outcome in resected pancreatic neuroendocrine tumors (pNET). (2015) (1)
Abstract 1155: Promoter CpG island hypermethylation of Decoy Receptor 1 (DCR1) is associated with poor response to irinotecan in colorectal cancer. (2013) (1)
Bisulfite PCR-Based Techniques for the Study of DNA Methylation (2004) (1)
Correction to "A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)" [Oncotarget. 2016; 7(18): 25950-61]. doi: 10.18632/oncotarget.7436 (2017) (0)
WRN Promoter CpG island hypermethylation does not predict a favourable outcome for irinotecan-treated metastatic colorectal cancer patients (2015) (0)
Promoter CpG island hypermethylation of Decoy Receptor 1 (DCR1) is associated with poor response to irinotecan in metastatic colorectal cancer (2014) (0)
SBRT Treatment Planning With VMAT Versus IMRT: Impact of Duodenal Sparing on Tumor Coverage in Patients With Locally Advanced Pancreatic Adenocarcinoma (2012) (0)
Methylation of CDO 1 , HOXA 9 , and TAC 1 for the Diagnosis of Lung Cancer (2014) (0)
Gefitinib and Radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck ” (2008) (0)
Advances in Brief Gene Promoter Hypermethylation in Tumors and Serum of Head and Neck Cancer Patients 1 (2000) (0)
Active Chromatin around the Transcription Start Site DNA Methylation by Preservation of Unmethylated DNA and hTERT Is Expressed in Cancer Cell Lines Despite Promoter (2006) (0)
Cancer Therapy: Clinical A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors (2009) (0)
Correction to: Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth (2018) (0)
SHORT REPORT Epigenetic silencing of multiple genes in primary CNS lymphoma (2006) (0)
Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma (2018) (0)
ning a Gene Promoter Methylation Signature in Sputum for Lung Cancer Risk Assessment (2012) (0)
Biomarker Insights DNA Methylation at the Novel CpG Sites in the Promoter of MED15 / PCQAP Gene as a Biomarker for Head and Neck Cancers (2014) (0)
SU‐E‐J‐170: Dosimetric Consequences of Uncorrected Rotational Setup Errors During Stereotactic Body Radiation Therapy (SBRT) Treatment of Pancreatic Cancers (2015) (0)
Lung carcinogenesis tracked by DNA methylation mapping in exhaled breath. (2006) (0)
Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter (2007) (0)
Identification of a DNA Methylation Predictive Signature of Overall Survival in Higher-Risk MDS Patients Treated with Azacitidine, (2011) (0)
Predicting sensitivity to azacytidine in non-small cell cancer lines by absence of activating mutations. (2012) (0)
High throughput DNA methylation analysis on a droplet-in-oil polymerase chain reaction array (2009) (0)
Doctorate Program in Molecular Oncology and Endocrinology XVIII cycle-2002–2006 Coordinator: Prof. Giancarlo Vecchio “NOVEL MECHANISMS RESPONSIBLE FOR CONTROLLING GLUCOSE-INDUCED INSULIN SECRETION IN PANCREATIC BETA-CELLS” (2006) (0)
Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules (2020) (0)
Comprehensivegenomiccharacterization of squamous cell lung cancers (2012) (0)
Defining the association of methylation biomarkers for establishing lung cancer risk: A nested case-control study of a high-risk cohort (2003) (0)
Aberrant DNA Methylation Patterns in Chronic Idiopathic Myelofibrosis. (2004) (0)
Abstract 4025: Evaluation of homologous recombination (HR) genes in myeloproliferative neoplasms (MPNs) suggests BRCA1 as a potential biomarker for sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition and disease progression (2012) (0)
INTERACTION BETWEEN THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR AND PDK 1 AS POTENTIAL THERAPEUTIC TARGET IN NEOPLASTIC CELLS ” (2007) (0)
Doctorate Program in Molecular Oncology and Endocrinology (2006) (0)
Abstract 3142: Hypermethylation of the tissue inhibitor of metalloproteinases-2 gene in multiple myeloma (2012) (0)
Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer (2018) (0)
The impact of multi-agent chemotherapy and stereotactic body radiation therapy on clinical outcomes in patients with unresectable pancreatic adenocarcinoma (2016) (0)
Methylation du gene socs-1 dans le cancer (2002) (0)
Methylation inactivates critical pathways in tumourgenesis (1999) (0)
299 SOCS1 methylation and azacitidine response in high risk myelodysplasia (MDS) and secondary acute myeloid leukemia (AML) (2011) (0)
Meeting Report of the Fifth International Cancer Epigenetics Conference in Beijing, China, October 2016. (2017) (0)
Abstract 652:GPX3promoter hypermethylation predicts platinum sensitivity in colorectal cancer cells. (2013) (0)
Abstract 3308: Urine epigenetic biomarkers for NSCLC diagnosis (2018) (0)
Compositions and methods to detect a neoplasm (2011) (0)
Pcft Is Silenced By DNA Methylation In Pediatric Acute Lymphoblastic Leukemia Resulting In Decreased Methotrexate Uptake (2013) (0)
Abstract 200: Methylation of GATA4 and GATA5 transcription factor genes in gastric cancers (2010) (0)
Using CHFR expression to predict response and survival after first line treatment with carboplatin-paclitaxel in NSCLC. (2012) (0)
Aberrant promoter methylation in sputum and serum for lung cancer detection (2002) (0)
SF-079-1 Using DNA methylation markers to predict early recurrence and to re-stage patients with stage I lung cancer (2008) (0)
P-242 HIV and lung cancer patients: Why such poor survival? (2005) (0)
Advances in Brief E-Cadherin Expression Is Silenced by DNA Hypermethylation in Human Breast and Prostate Carcinomas 1 (2006) (0)
Abstract S4-8: Promoter CpG Methylation ofBRCA1Predicts Sensitivity to PARP Inhibitors in Breast Cancer (2010) (0)
Abstract 2618: DNMT1 as a marker of differential sensitivities to epigenetic therapy of a Kras mutant and Kras wild type human non small cell lung cancer cell line (2011) (0)
Methode de prediction de la reaction clinique a un traitement chimiotherapeutique avec des agents alkylants (2001) (0)
Gene methylation and cytogenetic abnormalities in patients (pts) with higher-risk myelodysplastic syndromes. (2010) (0)
Histone deacetylase inhibitors and demethylating agents (2015) (0)
Cancer esearch apeutics , Targets , and Chemical Biology rrant Silencing of Cancer-Related Genes by CpG ermethylation Occurs Independently of Their R tial Organization in the Nucleus (2010) (0)
The CpG island methylator phenotype (CIMP): What’s in a name? (2013) (0)
Molecular mechanisms of insulin resistance : role of endocannabinoid system in the regulation of glucose metabolism and insulin action ” (2007) (0)
Epigenetic Dysregulation of the Tissue Inhibitor of Metalloproteinases-2 Gene in Multiple Myeloma (2011) (0)
Human Thyroid Carcinoma Papillary , Follicular , Hurthle ' s Cell , and Poorly Differentiated Distinct Patterns of E-Cadherin CpG Island Methylation in Updated (2006) (0)
Epigenetic Inactivation of the Secreted Frizzled-Related Protein Gene Family in Multiple Myeloma. (2007) (0)
Abstract B78: Referral delay after community diagnosis of non-small cell lung cancer impairs survival. (2012) (0)
SU-E-T-170: Characterization of the Location, Extent, and Proximity to Critical Structures of Target Volumes Provides Detail for Improved Outcome Predictions Among Pancreatic Cancer Patients (2015) (0)
Original Randomized controlled trial to evaluate the impact of aerobic exercise on visceral fat in overweight chronic kidney disease patients (2014) (0)
Pharmacoepigenomics in colorectal cancer (2008) (0)
N-Myc Downstream regulated gene 4 (NDRG4) promoter methylation is a sensitive and specific biomarker for colorectal cancer ambridge, Massachusetts (2007) (0)
GATA4 and GATA5 as tumor suppressors and biomarkers in colorectal cancer (2007) (0)
Correction to: Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth (2018) (0)
Abstract 3820: Ultrasensitive DNA methylation detection using sputum and plasma for early detection of NSCLC (2015) (0)
Sequential administration of DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi) induces apoptosis with caspase and reactive oxygen species (ROS)-dependent synergy (2007) (0)
A new immunohistochemistry prognostic score (IPS) for recurrence and survival in pancreatic neuroendocrine tumors (PanNET). (2016) (0)
Consumption of alcoholic beverages and the risk of nasopharyngeal carcinoma: a systematic review and meta‐analysis (2007) (0)
Identification of DNA methylation markers for early detection of CRC indicates a role for nervous system-related genes in CRC (2021) (0)
Human Primary Tumors Susceptibility to DNA Methylation in Normal Tissues and GermLine Variants in Methyl-Group Metabolism Genes and Updated Version (2002) (0)
Some observations on developing low grade 0 1 low stage tat 1 bladder cancer (1984) (0)
Abstract 3291: The human cancer DNA methylation marker atlas (2018) (0)
42. Utilization of Genomic Approaches to Identify the Hypermethylome of Colorectal Cancer - A Strategy for Biomarker Discovery (2008) (0)
Kidney , Brain , and Other Human Cancers Gene Suggests a Suppressor Role in Metalloproteinase-3 Methylation-associated Silencing of the Tissue Inhibitor of Updated Version (1999) (0)
Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer (2017) (0)
Erratum: Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer (Cancer Research (June 15, 2006) 66 (6210-6218)) (2007) (0)
Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma (2017) (0)
A Bioinformatics Pipeline for Cancer Epigenetics (2010) (0)
DNA methylation density analysis via fluorescent dye incorporation (2010) (0)
Field defect of methylation changes in esophageal adenocarcinomas in patients from Japan and the United States (2010) (0)
GATA4 and GATA5 act as tumor suppressors and are potential biomarkers in colorectal cancer (2008) (0)
The Identification of Epigenetic Biomarkers for Myeloid Malignancies (2011) (0)
Gene expression profile analysis of pituitary adenomas developed by HMGA transgenic mice ” (2007) (0)
DCR1 promoter hypermethylation and response to irinotecan in metastatic colorectal cancer (2016) (0)
9237 Array based CpG island methylation-profiling in acute myelogenous leukemia at diagnosis and relapse (2009) (0)
Breast Cancer Cells by Histone Deacetylase Inhibition in Human α Transcriptional Activation of Estrogen Receptor Updated (2000) (0)
790 Identification of Hypermethylated Tumor-specific Deoxyribonucleic Acid in Plasma of Patients with Glioma (2004) (0)
Technical considerations in PCR-based assay design for diagnostic DNA methylation cancer biomarkers (2022) (0)
Alleles in Neoplasia ink 4 Ap 16 Hypermethylation Can Selectively Silence Individual (2006) (0)
E-Cadherin Expression Is Silenced by 5 * CpG Island Methylation in Acute Leukemia 1 (2000) (0)
CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
New genes involved in the neoplastic transformation of the thyroid gland (2006) (0)
Abstract 3365: Epigenetic inactivation of PTPRT and sensitivity to STAT3 inhibition in lung cancer (2017) (0)
Molecular-based tumor cell screening at the lymph nodes of metastatic colorectal cancer patients predicts recurrence (1999) (0)
Abstract 4455: DNA methylation as biomarkers to predict early recurrence of T1-2N0 lung cancer (2016) (0)
CpG island methylation patterns in patients with chronic lymphocytic leukemia (2007) (0)
Radiation therapy for seminomatous testicular cancer (1981) (0)
Abstract A62: Clinical translation of liquid biopsy DNA methylation biomarkers: Lessons from two systematic reviews (2020) (0)
Abstract 3993: MiRNA-141 and methylation regulation of WNT signal pathway by suppressingSOX17 in esophageal cancer (2012) (0)
Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth (2017) (0)
Aberrant DNA Methylation of the C/EBPalpha Promoter Region in Hematopoietic Malignancies. (2005) (0)
The impact of DNA methylation on the identification of recurrent prostate cancer (2007) (0)
Methylation-specific Polymerase Chain Reaction Mapping of ER Gene CpG Island Methylation by Updated (2006) (0)
Advanced Lung Cancer Screening: An Individualized Molecular Nanotechnology Approach (2014) (0)
High throughput, quantitative DNA methylation screening using a quantum dot based nanotechnology assay (2008) (0)
Advances in Brief Hypermethylation Can Selectively Silence Individual pltfnk 4 A AlÃ-elesin Neoplasia 1 (2006) (0)
Abstract 1064: RASSF10 suppresses colorectal cancer growth by activating p53 signaling and sensitizes colorectal cancer cell to docetaxel (2015) (0)
A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and Refractory Disease) Acute Lymphoblastic Leukemia Or Bilineage/Biphenotypic Leukemia (2013) (0)
a-catenin Hypermethylation Correlates with AML Transformation in Patients with and without 5q Defects. (2007) (0)
Epigenetic heterogeneity in cancer (2019) (0)
Spreadsheet-Based Program for the Analysis (2001) (0)
DNA Hypermethylation in Cancer Dependence of Histone Modifications and Gene Expression on (2002) (0)
Abstract 5033: Azacitidine pretreatment sensitizes NSCLC cells to interferon-γ (2015) (0)
24 Epigenetic Changes in Cancer: From Discovery to Deployment (2012) (0)
Associations between O6MGMT and MLH1 promoter methylation and APC and KRAS gene mutations in colorectal cancer: indications for distinct pathways and sequence of events ambridge, Massachusetts (2007) (0)
Abstract 2491: Effect of HSP90 inhibitor ganetespib on stemness in small cell lung cancer (2016) (0)
Epigenetic Silencing of TMEM176A Activates ERK Signaling in Human Lung Cancer (2020) (0)
Differences in Promoter Methylation of Tumor Suppressor Genes in Cytogenetically Normal and Abnormal Acute Myeloid Leukemias. (2008) (0)
Exploring the cancer methylome (2012) (0)
GPX3 as a predictive biomarker in gastrointestinal malignancies. (2014) (0)
Abstract LB-92: Loss of a single Hic1 allele accelerates polyp formation in Apc mice (2010) (0)
Sparing Circulating Lymphocyte Populations With Endorectal Brachytherapy (2013) (0)
Abstract 3536: BRCA1 promoter methylation and homologous recombination repair status in primary chronic myeloid neoplasms. (2013) (0)
Progressive Chromatin Repression and Promoter Methylation of a-catenin Correlates with AML Transformation in Patients with and without 5q Deletions. (2008) (0)
Abstract ED03-04: Using epigenetic biomarkers as prognostic and predictive markers in non-small cell lung cancer (NSCLC) and the promise of epigenetic therapy (2011) (0)

This paper list is powered by the following services:

Other Resources About James G. Herman

en.wikipedia.org

What Schools Are Affiliated With James G. Herman?

James G. Herman is affiliated with the following schools:

James G. Herman's Academic­Influence.com Rankings

James G. Herman's Degrees

Why Is James G. Herman Influential?

James G. Herman's Published Works

Published Works

Other Resources About James G. Herman

What Schools Are Affiliated With James G. Herman?

James G. Herman's AcademicInfluence.com Rankings